

Applicant : Or et al.
Serial Number : 09/975,923
Filed : October 12, 2001
Page : 3

REMARKS

Applicants respectfully request entry of this amendment prior to the first Office Action on the merits in the above-identified application. Claims 1 to 12 were included in the application as originally filed. Claims 13 and 14 are added herein, and claim 3 is amended herein. Therefore claims 1 – 14 are currently pending.

No new matter has been added. Specifically, support for the amendment to claim 3 is provided in the specification at page 8, lines 6-10. Support for new claims 13 and 14 is provided in the specification at page 10, lines 12 to 14.


Attached hereto is a marked-up version of the changes made to the claims by the current amendment.

Allowance of the claims is earnestly solicited.

Respectfully submitted,

Date:

December 13, 2002




Jason D. Ferrone
Reg. No. P-52,887
Enanta Pharmaceuticals, Inc.
Direct Dial (617) 607-0747

Applicant : Or et al.
 Serial Number : 09/975,923
 Filed : October 12, 2001
 Page : 4

VERSION WITH MARKINGS TO SHOW CHANGES

3. A cyclosporin analog of formula I according to Claim 1 or a pro-drug or a pharmaceutically acceptable salt thereof, ~~wherein in formula I:~~

(i) A is of the formula ~~A1 or A2~~, wherein:



wherein

X is absent; and

Y is selected from a group consisting of:

- i. $-C(O)-O-R_1$ where R_1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio;
- ii. $-C(O)-S-R_1$ where R_1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy, halogen substituted C1-C6 alkylthio; and
- iii. $C(O)-OCH_2-OC(O)R_2$ where R_2 is C1-C6 alkyl optionally substituted with halogen,

• Applicant : Or et al.
Serial Number : 09/975,923
Filed : October 12, 2001
Page : 5

C1-C6 alkoxy, C1-C6 alkylthio,
heterocyclics or aryl;

- (ii) B is - α Abu-; and
- (iii) U is -(D)Ala-.